They also observed an increase in GLP-1R expression following treatment with exenatide.[13] In addition, studies by Shigeoka and Knura et al have shown that GLP-1R expression is significantly lower in advanced prostate cancer patients with high Gleason scores compared to patients with early-stage prostate cancer. Here, GLP1R is linked to prostate carcinoma.